Bayer has announced the US Food and Drug Administration’s (FDA) approval of Eylea, an aflibercept solution for injection into the eye for the treatment of diabetic macular edema (DME).
The company said that DME is the third approved application for Eylea. The FDA approval is supported by a positive outcome from the Phase III VISTA-DME and VIVID-DME clinical trials, which included 862 patients.
Go deeper with GlobalData
The studies compared aflibercept solution given through monthly 2mg injections, 2mg given every two months after five initial monthly injections or macular laser photocoagulation as a baseline treatment and then as needed.
After one year, the mean changes in best-corrected visual acuity were significantly improved compared with the control group and were similar to each other in clinical trials.
According to Bayer, aflibercept solution for injection was generally well tolerated with similar overall incidence of adverse events (AEs), ocular serious AEs and non-ocular serious AEs across treatment groups and the control group in the clinical trials.
Eylea consists of portions of human vascular endothelial growth factor receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1 and formulated as an iso-osmotic solution for intravitreal administration.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataEylea was approved in many countries for treatment of patients with neovascular age-related macular degeneration and for visual impairment due to macular edema secondary to central retinal vein occlusion.
Bayer HealthCare and Regeneron Pharmaceuticals are collaborating on the global development of Eylea. In the US, Regeneron holds exclusive marketing rights to Eylea, while Bayer HealthCare has exclusive rights outside the US.
Image: Diabetic macular edema is common microvascular complication in people with diabetes. Photo: courtesy of National Eye Institute, National Institutes of Health.
